Position in TAK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$612,993
+$166,667 QoQ
Shares Held
33,099
+15.6% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in TAK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026&PARTNERS holds $20,795,732 across 16 Drug Manufacturers - Specialty & Generic names. TAK ranks #8 (2.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
79,179 | $9,359,749 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
5,510 | $3,267,319 | |
| 3 | VTRS |
Viatris Inc
|
175,717 | $2,373,936 | |
| 4 | LNTH |
Lantheus Holdings, Inc.
|
13,575 | $1,029,663 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
28,322 | $853,058 | |
| 6 | PBH |
Prestige Consumer Healthcare Inc.
|
14,321 | $848,805 | |
| 7 | ELAN |
Elanco Animal Health Inc
|
31,877 | $762,816 | |
| 8 | TAK |
Takeda Pharmaceutical Co Ltd
This page
|
33,099 | $612,993 |
All Filings in TAK
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $612,993 | 33,099 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $446,326 | 28,629 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $381,738 | 26,075 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $327,721 | 21,198 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $274,336 | 18,449 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $315,138 | 23,802 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $238,142 | 16,747 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $147,464 | 11,396 | Shares | Sole | 2024-07-24 | |
| 2024-03-31 | $153,859 | 11,077 | Shares | Sole | 2024-04-11 | |
| No filing history on record for this holder in this stock. | ||||||